Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Clovis NSCLC Drug Rociletinib Wins FDA Priority Review

This article was originally published in Scrip

Executive Summary

After the U.S. markets closed on Sept. 29, Clovis Oncology, Inc. said the FDA had granted a priority review to the firm's new drug application (NDA) for rociletinib as a treatment for patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer who have been previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register